冠心病患者治疗性血管生成和激光心肌血运重建试验中安慰剂效应的持续时间。
Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease.
作者信息
Rana Jamal S, Mannam Arjuna, Donnell-Fink Laurel, Gervino Ernesto V, Sellke Frank W, Laham Roger J
机构信息
Angiogenesis Research Center and Division of Cardiology and Cardiac Surgery, Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
出版信息
Am J Cardiol. 2005 Jun 15;95(12):1456-9. doi: 10.1016/j.amjcard.2005.02.013.
The long-term beneficial effects of placebo therapy were evaluated in angiogenesis and laser myocardial revascularization trials in patients who had end-stage coronary heart disease. Improvements in mean angina class, exercise treadmill time, and quality of life were mostly maintained at 30 +/- 6 months of follow-up. Persistence of effect cannot be used as evidence of efficacy, and double-blinded trials are essential in this patient population.
在终末期冠心病患者的血管生成和激光心肌血运重建试验中，对安慰剂治疗的长期有益效果进行了评估。平均心绞痛分级、运动平板试验时间和生活质量的改善在30±6个月的随访中大多得以维持。效果的持续性不能用作疗效的证据，并且双盲试验对于该患者群体至关重要。
Zotero 插件